C1 Esterase Inhibitor (Berinert)

Berinert is covered for treatment of acute attacks and for prophylaxis of hereditary angioedema (HAE) due to C1‑INH deficiency (Type I or II) and is not covered for other forms of angioedema or HAE with normal C1‑INH unless specifically supported. Coverage requires baseline lab confirmation of low functional C1‑INH (<50% of normal) and low serum C4, prescription by or consultation with an HAE specialist, dosing limited to 20 IU/kg IV no more than once daily, and annual authorization with documentation of clinical benefit for reauthorization.

"Berinert is indicated for the treatment of acute attacks of Hereditary Angioedema (HAE)."

Sign up to see full coverage criteria, indications, and limitations.